Gideon E. Bollag
Opna Bio (United States) · 359 works · 29,947 citations · h-index 66
Top works
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21
- RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- A novel serine kinase activated by rac1/CDC42Hs‐dependent autophosphorylation is related to PAK65 and STE20.
- Discovery of a novel Raf kinase inhibitor.
- Hyperactive Ras in developmental disorders and cancer
- Regulators and Effectors of ras Proteins
- Somatic mutations in the neurofibromatosis 1 gene in human tumors
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- Direct Stimulation of the Guanine Nucleotide Exchange Activity of p115 RhoGEF by Gα 13
- Germline KRAS mutations cause Noonan syndrome
- Differential regulation of rasGAP and neurofibromatosis gene product activities
- RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
- Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells
- Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity.
- Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor
- Vemurafenib: the first drug approved for BRAF-mutant cancer